The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II trial of immunotherapeutic HPV vaccine PRGN-2009 with pembrolizumab before standard treatment in subjects with newly diagnosed HPV-associated oropharyngeal cancer.
 
Dara Mark Bracken-Clarke
(OPTIONAL) Uncompensated Relationships - LEO Pharma
 
Clint Allen
No Relationships to Disclose
 
Elisabetta Xue
Honoraria - Emcure
 
Marissa Mallek
No Relationships to Disclose
 
Lisa M. Cordes
No Relationships to Disclose
 
Seth M. Steinberg
No Relationships to Disclose
 
Jenn Marte
No Relationships to Disclose
 
Jason M. Redman
No Relationships to Disclose
 
Danielle M. Pastor
No Relationships to Disclose
 
Renee N. Donahue
No Relationships to Disclose
 
Jeffrey Schlom
Research Funding - Bavarian Nordic (Inst); EMD Serono/Merck (Inst); ImmunityBio (Inst); Incyte (Inst); NextCure (Inst); PDS Biotechnology (Inst); Pfizer (Inst); Precigen (Inst); Syndax (Inst); Syntrix Biosystems (Inst)
Patents, Royalties, Other Intellectual Property - If applicable; If applicable (Inst)
 
James L. Gulley
Research Funding - Astellas Medivation (Inst); Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); ImmunityBio (Inst); Incyte (Inst); Janssen Oncology (Inst); Kite, a Gilead company (Inst); Marengo Therapeutics (Inst); Merck (Inst); NextCure (Inst); PDS Biotechnology (Inst); Pfizer (Inst); Precigen (Inst); Syndax (Inst); Syntrix Biosystems (Inst)
Patents, Royalties, Other Intellectual Property - COMBINATION PDL1 AND TGF-BETA BLOCKADE IN PATIENTS WITH HPV+ MALIGNANCIES Publication number: 20200062849 Abstract: The invention provides a method of inhibiting a malignancy associated with human papilloma virus (HPV) comprising administering to a subje
 
Charalampos S. Floudas
No Relationships to Disclose